A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Public ClinicalTrials.gov record NCT00279422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
Study identification
- NCT ID
- NCT00279422
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2006
- Primary completion
- Jul 31, 2007
- Completion
- Jul 31, 2007
- Last update posted
- Mar 11, 2012
2006 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Gainesville | Florida | 32608 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Lexington | Kentucky | 40536 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Galveston | Texas | 77555-0764 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00279422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2012 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00279422 live on ClinicalTrials.gov.